ATE528405T1 - Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren - Google Patents

Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren

Info

Publication number
ATE528405T1
ATE528405T1 AT07015653T AT07015653T ATE528405T1 AT E528405 T1 ATE528405 T1 AT E528405T1 AT 07015653 T AT07015653 T AT 07015653T AT 07015653 T AT07015653 T AT 07015653T AT E528405 T1 ATE528405 T1 AT E528405T1
Authority
AT
Austria
Prior art keywords
eiav
based vectors
anemia virus
equine infectious
infectious anemia
Prior art date
Application number
AT07015653T
Other languages
English (en)
Inventor
Alan John Kingsman
Kyriacos Mitrophanous
Miles William Carroll
Narry Kim
Jonathan Rohll
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727135.7A external-priority patent/GB9727135D0/en
Priority claimed from GBGB9811037.2A external-priority patent/GB9811037D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE528405T1 publication Critical patent/ATE528405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15061—Methods of inactivation or attenuation
    • C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
AT07015653T 1997-12-22 1998-12-22 Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren ATE528405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9727135.7A GB9727135D0 (en) 1997-12-22 1997-12-22 Non-primate lentiviral vectors
GBGB9811037.2A GB9811037D0 (en) 1998-05-22 1998-05-22 Proretoviral vectors

Publications (1)

Publication Number Publication Date
ATE528405T1 true ATE528405T1 (de) 2011-10-15

Family

ID=26312829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07015653T ATE528405T1 (de) 1997-12-22 1998-12-22 Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren

Country Status (12)

Country Link
US (3) US6312683B1 (de)
EP (2) EP1042493A1 (de)
JP (1) JP4578678B2 (de)
CN (1) CN1322137C (de)
AT (1) ATE528405T1 (de)
AU (1) AU760287B2 (de)
CA (1) CA2315269A1 (de)
CY (1) CY1112196T1 (de)
DK (1) DK1895010T3 (de)
ES (1) ES2373406T3 (de)
PT (1) PT1895010E (de)
WO (1) WO1999032646A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
DK1895010T3 (da) * 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
AU2001240078A1 (en) * 2000-03-07 2001-09-17 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
CA2399399A1 (en) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
BR0113745A (pt) * 2000-09-09 2004-03-02 Akzo Nobel Nv Vacina, teste diagnóstico e métodos para imunizar mamìferos e para preparar uma vacina
US6585978B1 (en) * 2000-09-09 2003-07-01 Akzo Nobel EIA vaccine and diagnostic
US20040018211A1 (en) * 2002-06-26 2004-01-29 Ronald Montelaro EIA vaccine and diagnostic
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
ES2262680T3 (es) * 2000-09-14 2006-12-01 Ares Trading S.A. Uso de una quimera il-6r/il-6 en la enfermedad de huntington.
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
AU2002213398A1 (en) * 2000-10-20 2002-05-06 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
AU2002327755A1 (en) * 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
JP2005504539A (ja) * 2001-10-02 2005-02-17 インスティテュット クレイトン ド ラ リシェルシュ 制限発現レンチウイルス性ベクターに関連する方法及び組成物並びにその応用
EP1458879A2 (de) * 2001-12-21 2004-09-22 Oxford Biomedica (UK) Limited Verfahren zur herstellung eines transgenen organismus unter verwendung eines lentiviralen expressionsvektors wie z.b. eiav
US20030121062A1 (en) * 2001-12-21 2003-06-26 Oxford Biomedica (Uk) Limited Transgenic organism
EP2348119B1 (de) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronische lentiviraler Vektor
US9738907B2 (en) 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
US7662625B2 (en) * 2002-07-02 2010-02-16 Cancer Research Technology Limited Methods for detecting the differentiation status of cells using 5T4 antigen expression
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
JP4992032B2 (ja) * 2002-09-03 2012-08-08 オックスフォード バイオメディカ（ユーケー）リミテッド レトロウイルスベクター
AU2003268546A1 (en) * 2002-09-06 2004-03-29 Massachusetts Institute Of Technology Lentiviral vectors, related reagents, and methods of use thereof
CA2506798C (en) * 2002-11-22 2013-01-22 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
EP1606419A1 (de) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systeme und methoden zur erhohung der milchproduktion in tieren
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
ATE545699T1 (de) 2003-06-18 2012-03-15 Genelux Corp Modifizierte, rekombinante vacciniaviren und deren verwendungen
EP1689858B1 (de) 2003-11-13 2013-05-15 University Of Georgia Research Foundation, Inc. Verfahren zur charakterisierung des ibd (infectious bursal disease)-virus
US20050202484A1 (en) 2004-02-19 2005-09-15 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US20060233757A1 (en) * 2004-08-27 2006-10-19 Wendy Maury Vectors with viral insulators
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
EP2097517B1 (de) 2006-10-16 2014-06-04 Genelux Corporation Rekombinantes Lister-Stamm Vaccinia Virus kodierend für einen einzelkettigen anti-VEGF Antikörper
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
CN101705246B (zh) * 2007-04-29 2012-06-27 中国农业科学院哈尔滨兽医研究所 慢病毒基因转移载体、其制备方法和应用
CA2705862C (en) 2007-11-16 2018-03-27 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
DK2414386T3 (en) 2009-04-03 2016-02-22 Merial Ltd Birds of vaccines with newcastle disease virus vectors
MX344103B (es) 2010-08-31 2016-12-05 Merial Ltd Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694677A2 (de) 2011-04-04 2014-02-12 Netherland Cancer Institute Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung mit proteinkinasehemmern
EP2694678A2 (de) 2011-04-04 2014-02-12 Netherland Cancer Institute Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
EP2701736A1 (de) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Trunkierte hiv-hüllproteine (env), verfahren und zugehörige zusammensetzungen
EP2714077B1 (de) 2011-06-01 2018-02-28 Merial, Inc. Nadellose verabreichung von prrsv-impfstoffen
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014093965A1 (en) * 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
MX2017005687A (es) 2014-11-03 2017-08-21 Merial Inc Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112017027895A2 (pt) 2015-06-23 2018-11-06 Merial Inc vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
EP3380620A1 (de) 2015-11-23 2018-10-03 Novartis AG Optimierte lentivirale transfervektoren und verwendungen davon
EP3595705A1 (de) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Verfahren
ES2951857T3 (es) 2017-12-22 2023-10-25 Oxford Biomedica Ltd Vector retroviral
SG11202011015QA (en) 2018-05-15 2020-12-30 Flagship Pioneering Innovations V Inc Fusosome compositions and uses thereof
AU2019301053A1 (en) 2018-07-09 2021-01-28 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
SG11202105079QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
EP3880832A1 (de) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosomzusammensetzungen zur verabreichung von hämatopoetischen stammzellen
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
US20220333132A1 (en) 2019-09-03 2022-10-20 Sana Blotechnology, Inc. Cd24-associated particles and related methods and uses thereof
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
KR20220154734A (ko) 2020-03-13 2022-11-22 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터
MX2022012191A (es) 2020-03-31 2023-01-05 Sana Biotechnology Inc Partículas lipídicas dirigidas y composiciones y usos de estas.
BR112022021918A2 (pt) 2020-04-27 2023-03-14 Univ Iowa Res Found Composições e métodos para o tratamento de fibrose cística
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2022047316A1 (en) 2020-08-28 2022-03-03 Sana Biotechnology, Inc. Modified anti-viral binding agents
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
CA3205464A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4262828A1 (de) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumorinfiltrierende lymphozyten und anti-cd47-therapeutika
TW202242121A (zh) 2021-01-11 2022-11-01 美商薩那生物科技公司 靶向cd8之病毒載體之用途
CA3213076A1 (en) * 2021-03-24 2022-09-29 Danielle Jessica Yoesep Systems and methods for cell-free polypeptide synthesis
CN117642420A (zh) 2021-05-28 2024-03-01 萨那生物科技公司 含有截短的狒狒内源性逆转录病毒(BaEV)包膜糖蛋白的脂质颗粒及相关方法和用途
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
TW202321456A (zh) * 2021-09-08 2023-06-01 日商寶生物股份有限公司 反轉錄病毒載體製造用之核酸
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
JP3247972B2 (ja) * 1990-05-28 2002-01-21 財団法人阪大微生物病研究会 レトロウイルス遺伝子の多量発現能と翻訳後のプロセッシング能とを兼備するプラスミドの作製法、及びこれより得られるプラスミドとその発現産物
WO1991019798A1 (en) 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
AU2007392A (en) 1991-05-29 1993-01-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Eukaryotic expression vectors with regulation of rna processing
JPH06261764A (ja) 1993-02-17 1994-09-20 Wisconsin Alumni Res Found 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
JP4303315B2 (ja) * 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
WO1995030755A1 (fr) 1994-05-10 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
DK0779929T5 (da) * 1994-09-02 2001-08-13 Gsf Forschungszentrum Umwelt Ikke-selvinaktiverende, ekspressionsmålrettede retrovirale vektorer
US6300118B1 (en) * 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6033672A (en) * 1996-03-15 2000-03-07 University Of Southern California Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens
HUP0000421A2 (hu) * 1996-10-17 2000-06-28 Oxford Biomedica (Uk) Limited Retrovirális vektorok
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
KR100556864B1 (ko) * 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 렌티바이러스-기원 유전자 전달 벡터
GB9720465D0 (en) * 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
CA2304983A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DK1895010T3 (da) * 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vektorer baseret på virus for infektiøs hesteanæmi (eiav)

Also Published As

Publication number Publication date
US6312683B1 (en) 2001-11-06
CA2315269A1 (en) 1999-07-01
EP1895010A3 (de) 2008-04-16
ES2373406T3 (es) 2012-02-03
CY1112196T1 (el) 2015-12-09
JP2002516065A (ja) 2002-06-04
AU1773299A (en) 1999-07-12
EP1895010B1 (de) 2011-10-12
CN1322137C (zh) 2007-06-20
AU760287B2 (en) 2003-05-08
EP1895010A2 (de) 2008-03-05
WO1999032646A1 (en) 1999-07-01
CN1285000A (zh) 2001-02-21
DK1895010T3 (da) 2011-11-21
US20060024274A1 (en) 2006-02-02
JP4578678B2 (ja) 2010-11-10
PT1895010E (pt) 2012-01-25
US20030147907A1 (en) 2003-08-07
EP1042493A1 (de) 2000-10-11

Similar Documents

Publication Publication Date Title
ATE528405T1 (de) Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
ATE358732T1 (de) Anti-virale vektoren
HUP0000442A2 (hu) Lentivirális vektorok
ATE213780T1 (de) Retrovirale vektoren
ES2154624T1 (es) Regulacion de la expresion de la quinolato fosforribosil transferasa.
EP0783321A4 (de) Virale nukleotidsequenz vr-2332 und nutzungsverfahren
EE9900581A (xx) LAG-3 pleissimisteisendid
DK0854197T3 (da) Primere til påvisning af HIV-1
ES2143475T3 (es) Genes de polifenol oxidasa.
DK0404625T3 (da) Oligonukleotidsekvenser til amplifikation af genomer af retrovirus af HIV-2 og SIV-typen samt deres anvendelser til in vitro-diagnose af infektioner forårsaget af disse virus
DE69121975D1 (de) Spezifischer Nachweis von Mycobacterium Tuberculosis
DK0630409T3 (da) Defekt-pakkende ikke-onkovirus-vektorer baseret på MPMV
DK0431128T3 (da) Vektor, der koder for selvsamlende, defekte, ikke-selvopformerende viruspartikler
AU5120796A (en) DNA fragment, recombination vector containing the same and method for expressing foreign genes using the same
ATE229345T1 (de) Cdna klon für den südafrikanischen arbovirus no.86
BR8506990A (pt) Vetores de clonagem ou de expressao comportando o genoma do virus de eritroblastose aviaria e celulas transfectadas por estes vetores
IL108779A (en) Polyribozyme capable of conferring viral resistance to plants, and resistant plants producing said riboyzme
DE69232351T2 (de) Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist
AU3955400A (en) The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application
ATE180015T1 (de) N-carbamoylsarcosin-amidohydrolase, kloniert

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1895010

Country of ref document: EP